CSIMarket
 


Ocular Therapeutix Inc   (OCUL)
Other Ticker:  
 
 

OCUL's Revenue Growth by Quarter and Year

Ocular Therapeutix Inc 's Revenue results by quarter and year




OCUL Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 12.31 7.35 2.26
III Quarter September 11.97 12.15 5.88 0.83
II Quarter June 12.27 11.72 1.57 0.65
I Quarter March 13.19 7.34 2.61 0.49
FY   37.43 43.52 17.41 4.23



OCUL Revenue third quarter 2022 Y/Y Growth Comment
Ocular Therapeutix Inc reported decrease in Revenue in the third quarter 2022 by -1.52% to $ 11.97 millions, from the same quarter in 2021.
The decrease in the third quarter 2022 Ocular Therapeutix Inc 's Revenue compares unfavorably to the Company's average Revenue increase of 14.92%.

Looking into third quarter 2022 results within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue growth. While Ocular Therapeutix Inc ' s Revenue decline of -1.52% ranks overall at the positon no. 1399 in the third quarter 2022.




OCUL Revenue ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - 67.48 % 225.22 % 352 %
III Quarter September -1.52 % 106.63 % 608.43 % 66 %
II Quarter June 4.69 % 646.5 % 141.54 % 0 %
I Quarter March 79.7 % 181.23 % 432.65 % 44.12 %
FY   - 149.97 % 311.58 % 112.56 %

Financial Statements
Ocular Therapeutix Inc 's third quarter 2022 Revenue $ 11.97 millions OCUL's Income Statement
Ocular Therapeutix Inc 's third quarter 2021 Revenue $ 12.15 millions Quarterly OCUL's Income Statement
New: More OCUL's historic Revenue Growth >>


OCUL Revenue (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - 1.32 % 25 % 172.29 %
III Quarter September -2.49 % 3.67 % 274.52 % 27.69 %
II Quarter June -6.97 % 59.67 % -39.85 % 32.65 %
I Quarter March 7.15 % -0.14 % 15.49 % -2 %
FY (Year on Year)   - 149.97 % 311.58 % 112.56 %




Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #173
Overall #1399

Revenue Y/Y Growth Statistics
High Average Low
70.79 % 14.92 % -7.02 %
(Dec 31 2019)   (Mar 31 2018)
Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #173
Overall #1399
Revenue Y/Y Growth Statistics
High Average Low
70.79 % 14.92 % -7.02 %
(Dec 31 2019)   (Mar 31 2018)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Ocular Therapeutix Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
274.51 % 21.61 % -39.86 %
(Sep 30 2020)  


OCUL's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2022 Ocular Therapeutix Inc reported fall in Revenue from the second quarter by -2.49% to $ 11.97 millions, from $ 12.27 millions achived in the previous quarter.

Although periodic influence normally energize III. Quarter 2022 performance, it clearly has not been enough to salvage Ocular Therapeutix Inc 's III. Quarter 2022 outcome, Joseph  Clarke, Major Pharmaceutical Preparations industry insider allocated in Boston wrote.

Within Major Pharmaceutical Preparations industry 63 other companies have achieved higher Revenue quarter on quarter growth. While Ocular Therapeutix Inc 's Revenue growth quarter on quarter, overall rank is 1264.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #64
Healthcare Sector #170
Overall #1264
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #64
Healthcare Sector #170
Overall #1264
Revenue Q/Q Growth Statistics
High Average Low
274.51 % 21.61 % -39.86 %
(Sep 30 2020)  


OCUL's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2022 Ocular Therapeutix Inc reported fall in Revenue from the second quarter by -2.49% to $ 11.97 millions, from $ 12.27 millions declared a quarter before.

Even seasonal circumstance which normally fuel III. Quarter 2022 Revenue, that simply could not be sufficient to salvage Major Pharmaceutical Preparations's company III. Quarter achievement, Joseph  Clarke, Major Pharmaceutical Preparations industry insider allocated in Boston wrote and wrote that average quarter on quarter Revenue growth is at 21.61% for OCUL.

Within Major Pharmaceutical Preparations industry 63 other companies have achieved higher Revenue quarter on quarter growth. While Ocular Therapeutix Inc 's Revenue growth quarter on quarter, overall rank is 1264.


Ocular Therapeutix Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
Cumulative Revenue 12 Months Ending $ 49.73 $ 49.92 $ 49.37 $ 43.52 $ 38.56
Y / Y Revenue Growth (TTM) 28.95 % 54.61 % 123.02 % 150.08 % 213.26 %
Year on Year Revenue Growth Overall Ranking # 458 # 662 # 255 # 174 # 154
Seqeuential Revenue Change (TTM) -0.38 % 1.11 % 13.43 % 12.86 % 19.44 %
Seq. Revenue Growth (TTM) Overall Ranking # 1399 # 2540 # 461 # 767 # 185




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2022 period, Ocular Therapeutix Inc 's cumulative twelve months Revenue were $ 50 millions, company would post below average annual Revenue growth of 19.44% year on year, if the fiscal year would end at Sep 30 2022.
A slow-down in the Ocular Therapeutix Inc 's Revenue growth from the 12.27% growth in Jun 30 2022.

In the Healthcare sector 73 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 458, from total ranking in previous quarter at 662.

Revenue TTM Q/Q Growth Statistics
High Average Low
70.79 %
14.92 %
-7.02 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 54
Healthcare Sector # 74
Overall # 458

Revenue TTM Y/Y Growth Statistics
High Average Low
1787.5 %
177.45 %
-6.09 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 54
Sector # 173
S&P 500 # 1399
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2022 period, Ocular Therapeutix Inc 's cumulative twelve months Revenue were $ 50 millions, company would post below average annual Revenue growth of -6.09% year on year, if the fiscal year would end at Sep 30 2022.
A slow-down in the Ocular Therapeutix Inc 's Revenue growth from the 12.27% growth in Jun 30 2022.

In the Healthcare sector 73 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 458, from total ranking in previous quarter at 662.

Revenue TTM Q/Q Growth Statistics
High Average Low
70.79 %
14.92 %
-7.02 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 54
Healthcare Sector # 74
Overall # 458

Revenue TTM Y/Y Growth Statistics
High Average Low
1787.5 %
177.45 %
-6.09 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 54
Sector # 173
S&P 500 # 1399




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
OCUL's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for OCUL's Competitors
Revenue Growth for Ocular Therapeutix Inc 's Suppliers
Revenue Growth for OCUL's Customers

You may also want to know
OCUL's Annual Growth Rates OCUL's Profitability Ratios OCUL's Asset Turnover Ratio OCUL's Dividend Growth
OCUL's Roe OCUL's Valuation Ratios OCUL's Financial Strength Ratios OCUL's Dividend Payout Ratio
OCUL's Roa OCUL's Inventory Turnover Ratio OCUL's Growth Rates OCUL's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2022
Owens and Minor Inc -0.19%$ -0.191 millions
National Research Corporation-0.20%$ -0.201 millions
Livanova Plc-0.24%$ -0.241 millions
Healthcare Services Group Inc -0.27%$ -0.265 millions
Catalent Inc -0.29%$ -0.293 millions
Asensus Surgical Inc -0.31%$ -0.311 millions
Liquidia Corporation-0.43%$ -0.429 millions
Integra Lifesciences Holdings Corp-0.43%$ -0.432 millions
Pediatrix Medical Group Inc -0.62%$ -0.615 millions
China Pharma Holdings Inc -0.64%$ -0.642 millions
Acadia Pharmaceuticals Inc -0.68%$ -0.682 millions
Syneos Health Inc -0.89%$ -0.891 millions
Innovage Holding Corp -1.07%$ -1.070 millions
Procyon Corp-1.20%$ -1.200 millions
Precipio inc -1.38%$ -1.380 millions
Ati Physical Therapy Inc -1.40%$ -1.397 millions
Ocular Therapeutix Inc -1.55%$ -1.547 millions
Alpine Immune Sciences Inc -1.75%$ -1.750 millions
Surgalign Holdings Inc -1.79%$ -1.786 millions
Tenet Healthcare Corp-1.90%$ -1.900 millions
Teleflex Incorporated-1.92%$ -1.923 millions
Novocure Limited-1.95%$ -1.952 millions
Dynatronics Corporation-2.01%$ -2.014 millions
Royalty Pharma Plc-2.10%$ -2.101 millions
National Healthcare Corp-2.13%$ -2.130 millions
Fonar Corporation-2.27%$ -2.271 millions
Psychemedics Corp-2.35%$ -2.353 millions
Escalon Medical Corp -2.63%$ -2.626 millions
Lifevantage Corp-2.72%$ -2.724 millions
West Pharmaceutical Services Inc -2.77%$ -2.774 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

JENGQ's Profile

Stock Price

JENGQ's Financials

Business Description

Fundamentals

Charts & Quotes

JENGQ's News

Suppliers

JENGQ's Competitors

Customers & Markets

Economic Indicators

JENGQ's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071